{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:17:03Z","timestamp":1781680623560,"version":"3.54.5"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","drupjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.drup.2016.06.005","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T17:04:36Z","timestamp":1466960676000},"page":"72-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice"],"prefix":"10.1016","volume":"27","author":[{"given":"Selvi","family":"Durmus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"van Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred H.","family":"Schinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2016.06.005_bib0005","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1053\/gast.2001.24804","article-title":"LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers","volume":"120","author":"Abe","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2016.06.005_bib0010","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","article-title":"Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding","volume":"323","author":"Aller","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.drup.2016.06.005_bib0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10555-007-9049-z","article-title":"Molecular basis of antifolate resistance","volume":"26","author":"Assaraf","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.drup.2016.06.005_bib0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/jpet.106.104364","article-title":"Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants","volume":"318","author":"Badagnani","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/clpt.2008.95","article-title":"Pharmacogenetic pathway analysis of docetaxel elimination","volume":"85","author":"Baker","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0030","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/mol.57.4.760","article-title":"Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions","volume":"57","author":"Bakos","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0035","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1124\/mol.109.054791","article-title":"Structural determinants of imidazoacridinones facilitating antitumor activity are crucial for substrate recognition by ABCG2","volume":"75","author":"Bram","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0040","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1124\/dmd.105.003640","article-title":"Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps)","volume":"33","author":"Cheng","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2016.06.005_bib0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","article-title":"Role of anthracyclines in the era of targeted therapy","volume":"7","author":"Cortes-Funes","year":"2007","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.drup.2016.06.005_bib0050","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.LAB.0000065015.02412.48","article-title":"Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma","volume":"83","author":"Cui","year":"2003","journal-title":"Lab. Invest."},{"key":"10.1016\/j.drup.2016.06.005_bib0055","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1158\/1078-0432.CCR-12-0761","article-title":"Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel","volume":"18","author":"de Graan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2016.06.005_bib0060","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1021\/mp500330y","article-title":"Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine","volume":"11","author":"Drozdzik","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2016.06.005_bib0065","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2016.06.005_bib0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/1535-7163.MCT-14-0155","article-title":"Mechanisms of resistance to cabazitaxel","volume":"14","author":"Duran","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0075","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1021\/acs.molpharmaceut.5b00453","article-title":"Preclinical mouse models to study human OATP1B1- and OATP1B3-mediated drug\u2013drug interactions in vivo","volume":"12","author":"Durmus","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2016.06.005_bib0080","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ijc.28797","article-title":"In vivo disposition of doxorubicin is affected by mouse Oatp1a\/1b and human OATP1A\/1B transporters","volume":"135","author":"Durmus","year":"2014","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.drup.2016.06.005_bib0085","doi-asserted-by":"crossref","first-page":"13682","DOI":"10.1073\/pnas.0603236103","article-title":"Structural basis for ligand promiscuity in cytochrome P450 3A4","volume":"103","author":"Ekroos","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2016.06.005_bib0090","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.4161\/cbt.10.12.14085","article-title":"Cabazitaxel: filling one of the gaps in the treatment of prostate cancer","volume":"10","author":"Figg","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0095","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2217\/14622416.10.3.339","article-title":"Pharmacogenetics of the organic anion transporting polypeptide 1A2","volume":"10","author":"Franke","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.drup.2016.06.005_bib0100","first-page":"73","article-title":"Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier","volume":"294","author":"Gao","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0110","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/sj.clpt.6100056","article-title":"Intestinal drug transporter expression and the impact of grapefruit juice in humans","volume":"81","author":"Glaeser","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.drup.2016.06.005_bib0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-suppl_2-3","article-title":"Preclinical pharmacology of the taxanes: implications of the differences","volume":"9","author":"Gligorov","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.drup.2016.06.005_bib0120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2016.06.005_bib0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2133\/dmpk.DMPK-12-RV-099","article-title":"Impact of genetic variation in OATP transporters to drug disposition and response","volume":"28","author":"Gong","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.drup.2016.06.005_bib0130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/toxsci\/kfr114","article-title":"Characterization of organic anion-transporting polypeptide (Oatp) 1a1 and 1a4 null mice reveals altered transport function and urinary metabolomic profiles","volume":"122","author":"Gong","year":"2011","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.drup.2016.06.005_bib0135","first-page":"72","article-title":"Epidemiology of anthracycline cardiotoxicity in children and adults","volume":"25","author":"Grenier","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.drup.2016.06.005_bib0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejphar.2008.01.042","article-title":"Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3","volume":"584","author":"Gui","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2007.07.019","article-title":"Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer","volume":"59","author":"Han","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drup.2016.06.005_bib0150","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1073\/pnas.95.12.6636","article-title":"Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics","volume":"95","author":"Harlow","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2016.06.005_bib0155","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/dmd.113.054783","article-title":"Utility of Oatp1a\/1b-knockout and OATP1B1\/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein","volume":"42","author":"Higgins","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2016.06.005_bib0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5414\/CPP47061","article-title":"Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis","volume":"47","author":"Hilger","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00335-010-9284-4","article-title":"Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins","volume":"21","author":"Holmes","year":"2010","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.drup.2016.06.005_bib0170","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"Hu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2016.06.005_bib0175","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/bjc.2013.811","article-title":"Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations","volume":"110","author":"Hu","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2016.06.005_bib0180","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1097\/00002030-200211220-00009","article-title":"Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs","volume":"16","author":"Huisman","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.drup.2016.06.005_bib0185","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","article-title":"Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics","volume":"27","author":"Innocenti","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2016.06.005_bib0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ijc.28970","article-title":"Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel","volume":"136","author":"Iusuf","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2016.06.005_bib0195","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1535-7163.MCT-13-0541","article-title":"OATP1A\/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice","volume":"13","author":"Iusuf","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0200","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1021\/mp300108c","article-title":"Organic anion-transporting polypeptides 1a\/1b control the hepatic uptake of pravastatin in mice","volume":"9","author":"Iusuf","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2016.06.005_bib0205","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tips.2011.10.005","article-title":"Functions of OATP1A and 1B transporters in vivo: insights from mouse models","volume":"33","author":"Iusuf","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drup.2016.06.005_bib0210","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/clpt.2012.143","article-title":"Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification","volume":"92","author":"Iusuf","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0215","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1124\/mol.112.081927","article-title":"Murine Oatp1a\/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure","volume":"83","author":"Iusuf","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0220","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2125.2011.03963.x","article-title":"Population pharmacokinetic analysis of sorafenib in patients with solid tumours","volume":"72","author":"Jain","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0225","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40880-015-0003-0","article-title":"ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel","volume":"34","author":"Kathawala","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.drup.2016.06.005_bib0230","doi-asserted-by":"crossref","first-page":"14078","DOI":"10.1073\/pnas.241314798","article-title":"Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein","volume":"98","author":"Kondratov","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2016.06.005_bib0235","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/pr.113.007518","article-title":"Transporters and drug\u2013drug interactions: important determinants of drug disposition and effects","volume":"65","author":"Konig","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drup.2016.06.005_bib0240","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/clpt.2009.233","article-title":"Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel","volume":"87","author":"Koolen","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0245","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1124\/mol.111.077099","article-title":"P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine","volume":"82","author":"Lagas","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0250","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-12-0926","article-title":"Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics","volume":"12","author":"Lancaster","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0255","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/1535-7163.MCT-14-0547","article-title":"Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance","volume":"14","author":"Lee","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0260","doi-asserted-by":"crossref","first-page":"9610","DOI":"10.1074\/jbc.M411092200","article-title":"Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry","volume":"280","author":"Lee","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2016.06.005_bib0265","doi-asserted-by":"crossref","first-page":"C570","DOI":"10.1152\/ajpcell.00436.2008","article-title":"Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters","volume":"296","author":"Leuthold","year":"2009","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.drup.2016.06.005_bib0270","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/toxsci\/kfn038","article-title":"Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake\/toxicity of phalloidin and microcystin-LR","volume":"103","author":"Lu","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.drup.2016.06.005_bib0275","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1124\/mol.110.069971","article-title":"Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3","volume":"79","author":"Martinez-Becerra","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0280","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1568009023333890","article-title":"Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan","volume":"2","author":"Mathijssen","year":"2002","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.drup.2016.06.005_bib0285","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drup.2016.06.005_bib0290","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1535-7163.MCT-06-0500","article-title":"Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells","volume":"6","author":"Monks","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0295","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/j.1349-7006.2007.00570.x","article-title":"Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma","volume":"98","author":"Muto","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2016.06.005_bib0300","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2133\/dmpk.DMPK-11-RV-099","article-title":"Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs","volume":"27","author":"Nakanishi","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.drup.2016.06.005_bib0305","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/bdd.1915","article-title":"Putative roles of organic anion transporting polypeptides (OATPs) in cell survival and progression of human cancers","volume":"35","author":"Nakanishi","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.drup.2016.06.005_bib0310","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drup.2016.06.005_bib0315","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1158\/0008-5472.CAN-13-3634","article-title":"Influence of drug formulation on OATP1B-mediated transport of paclitaxel","volume":"74","author":"Nieuweboer","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2016.06.005_bib0320","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1124\/dmd.104.001909","article-title":"Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms","volume":"33","author":"Nozawa","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2016.06.005_bib0325","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-pharmtox-010510-100556","article-title":"The expression and function of organic anion transporting polypeptides in normal tissues and in cancer","volume":"52","author":"Obaidat","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.drup.2016.06.005_bib0330","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/bi500176e","article-title":"Cysteine scanning mutagenesis of transmembrane domain 10 in organic anion transporting polypeptide 1B1","volume":"53","author":"Ohnishi","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.drup.2016.06.005_bib0335","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbrc.2005.05.174","article-title":"Characterization of the organic cation transporter SLC22A16: a doxorubicin importer","volume":"333","author":"Okabe","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2016.06.005_bib0340","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1124\/dmd.108.024901","article-title":"Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and\/or ABCG2 inhibitors","volume":"37","author":"Oostendorp","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2016.06.005_bib0345","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/dmd.109.029454","article-title":"Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier","volume":"38","author":"Ose","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2016.06.005_bib0350","first-page":"117","article-title":"Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer","volume":"5","author":"Paller","year":"2011","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0355","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1124\/jpet.111.184564","article-title":"Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae)","volume":"339","author":"Roth","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0360","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2016.06.005_bib0365","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1124\/dmd.114.057976","article-title":"Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins","volume":"42","author":"Salphati","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2016.06.005_bib0370","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/mol.66.2.330","volume":"66","author":"Sasaki","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0375","first-page":"227","article-title":"The mechanism of ATP-dependent multidrug transport by P-glycoprotein","volume":"643","author":"Shapiro","year":"1998","journal-title":"Acta Physiol. Scand. Suppl."},{"key":"10.1016\/j.drup.2016.06.005_bib0380","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","article-title":"Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption","volume":"34","author":"Shitara","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.drup.2016.06.005_bib0385","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/clpt.2012.127","article-title":"Contribution of the OATP1B subfamily to cancer biology and treatment","volume":"92","author":"Sissung","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0390","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.tiv.2005.06.045","article-title":"Pharmacogenetics of irinotecan metabolism and transport: an update","volume":"20","author":"Smith","year":"2006","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.drup.2016.06.005_bib0395","doi-asserted-by":"crossref","first-page":"p4167","DOI":"10.1158\/1078-0432.CCR-14-0949","article-title":"Hepatic uptake transporters and docetaxel disposition in mice-letter","volume":"20","author":"Sparreboom","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2016.06.005_bib0400","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1124\/dmd.113.055806","article-title":"Uptake carriers and oncology drug safety","volume":"42","author":"Sprowl","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2016.06.005_bib0405","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/147323000002800401","article-title":"Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients","volume":"28","author":"Stangier","year":"2000","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.drup.2016.06.005_bib0410","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/B978-0-12-800223-0.00005-0","article-title":"Organic anion-transporting polypeptides","volume":"73","author":"Stieger","year":"2014","journal-title":"Curr. Top. Membr."},{"key":"10.1016\/j.drup.2016.06.005_bib0415","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.biopha.2011.04.031","article-title":"Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport","volume":"65","author":"Svoboda","year":"2011","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2016.06.005_bib0420","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00280-008-0864-x","article-title":"Life-threatening toxicities in a patient with UGT1A1*6\/*28 and SLCO1B1*15\/*15 genotypes after irinotecan-based chemotherapy","volume":"63","author":"Takane","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0425","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.coph.2013.08.011","article-title":"Genetically modified mouse models for oral drug absorption and disposition","volume":"13","author":"Tang","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0430","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/acs.molpharmaceut.5b00470","article-title":"P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain disposition and oral availability of the novel taxane cabazitaxel (jevtana) in mice","volume":"12","author":"Tang","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2016.06.005_bib0435","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1158\/1078-0432.CCR-13-1759","article-title":"P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice","volume":"20","author":"Tang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2016.06.005_bib0440","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1208\/s12248-015-9740-x","article-title":"Role of organic anion-transporting polypeptides (OATPs) in cancer therapy","volume":"17","author":"Thakkar","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.drup.2016.06.005_bib0445","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","article-title":"Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects","volume":"27","author":"Trevino","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2016.06.005_bib0450","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1172\/JCI59526","article-title":"Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver","volume":"122","author":"van de Steeg","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2016.06.005_bib0455","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/dmd.108.024315","article-title":"Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1)","volume":"37","author":"van de Steeg","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2016.06.005_bib0460","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","article-title":"Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice","volume":"19","author":"van de Steeg","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2016.06.005_bib0465","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1158\/1078-0432.CCR-10-1980","article-title":"High impact of Oatp1a\/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel","volume":"17","author":"Van de Steeg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2016.06.005_bib0470","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1172\/JCI42168","article-title":"Organic anion transporting polypeptide 1a\/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs","volume":"120","author":"van de Steeg","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2016.06.005_bib0475","first-page":"216","article-title":"Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review","volume":"60","author":"van Outryve","year":"2002","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.drup.2016.06.005_bib0480","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1158\/0008-5472.CAN-15-0280","article-title":"Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a\/1b","volume":"75","author":"Vasilyeva","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2016.06.005_bib0485","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.108.146647","article-title":"Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans","volume":"328","author":"Watanabe","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2016.06.005_bib0490","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10928-010-9176-y","article-title":"Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans","volume":"37","author":"Watanabe","year":"2010","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.drup.2016.06.005_bib0495","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/rheumatology\/kem279","article-title":"Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis","volume":"47","author":"Wessels","year":"2008","journal-title":"Rheumatology (Oxf.)"},{"key":"10.1016\/j.drup.2016.06.005_bib0500","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drup.2016.06.005_bib0505","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/01.fpc.0000230420.05221.71","article-title":"Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients","volume":"16","author":"Xiang","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.drup.2016.06.005_bib0510","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2007.10.040","article-title":"Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes","volume":"260","author":"Yamaguchi","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2016.06.005_bib0515","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/mol.108.046458","article-title":"Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2\/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin","volume":"74","author":"Zaher","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drup.2016.06.005_bib0520","doi-asserted-by":"crossref","first-page":"23538","DOI":"10.1074\/jbc.M303504200","article-title":"Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2)","volume":"278","author":"Zelcer","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2016.06.005_bib0525","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1081\/DMR-200028812","article-title":"Drug bioactivation, covalent binding to target proteins and toxicity relevance","volume":"37","author":"Zhou","year":"2005","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.drup.2016.06.005_bib0530","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/1078-0432.CCR-12-3306","article-title":"Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide","volume":"19","author":"Zimmerman","year":"2013","journal-title":"Clin. Cancer Res."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764616300176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764616300176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T06:48:45Z","timestamp":1568098125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764616300176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":106,"alternative-id":["S1368764616300176"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2016.06.005","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2016.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}